Xcout IntelNextCure, Inc.
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
Subscribe to see NextCure, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
NextCure, Inc. at a glance
NextCure, Inc. is a biotech company headquartered in Beltsville, United States. It is publicly listed (NXTC) with a market capitalisation of $22.7M. Xcout tracks 42 named people at NextCure, Inc., including Michael Richman (President and Chief Executive Officer).
NextCure, Inc. leadership
- Michael RichmanPresident and Chief Executive Officer
- Timothy MayerChief Operating Officer
- Timothy Mayer, Ph.D.COO
- Steven CobournChief Financial Officer
- Steven P. CobournCFO
- Udayan GuhaChief Medical Officer
36 more named people on record for NextCure, Inc., with roles, board committees and tenure — see the full roster →
NextCure, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $93.4M | 7 named | |
| Series A | $67M | 6 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent NextCure, Inc. news
- AcquisitionM&A registration (S-4)
- AcquisitionM&A communication (425)
- AcquisitionM&A registration (S-4)
- AcquisitionM&A communication (425)
9 corporate events on record, with sources — see the full timeline →
Investors
NextCure, Inc. competitors
A few of NextCure, Inc.'s closest competitors — see the full list of competitors and alternatives →
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
Normunity Holding Company, LLC is a biotechnology company developing novel anti-cancer therapies and biologic medicines, including therapeutic antibodies, bispecific antibodies, and T cell engagers. The company utilizes proprietary discovery platforms originating from a partnership with the Yale School of Medicine to target mechanisms at the interface of tumors and the immune system.
Checkmate Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing proprietary technology to stimulate the immune system to combat cancer.
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Nectin Therapeutics is an Israeli biotechnology company developing cancer immunotherapies that target nectin-family proteins, particularly Nectin-4. Its products are intended for oncology patients and healthcare providers treating solid tumors.
Get NextCure, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on NextCure, Inc. in Xcout Intel
- 42 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- 9 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access